BioXcel Therapeutics (BTAI) Other financing activities (2019 - 2026)

BioXcel Therapeutics has reported Other financing activities for 7 years, with the latest figure at $1.4 million in Q2 2026.

• On a quarterly basis, Other financing activities changed N/A year-over-year to $1.4 million in Q2 2026; TTM through Jun 2026 was $7.6 million, a 227.59% increase from a year earlier, with the FY2024 full-year figure at $2.5 million, up 400.0% from the prior year.
• Other financing activities was $1.4 million for Q2 2026 at BioXcel Therapeutics, down from $6.2 million in the prior quarter.
• The five-year high for Other financing activities was $6.2 million in Q1 2026, with the low at $224000.0 in Q1 2024.
• Average Other financing activities over 4 years is $2.1 million, with a median of $1.9 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Other financing activities jumped 2814.29% in 2022, then tumbled 92.3% in 2023.
• Over 4 years, Other financing activities stood at $3.1 million in 2022, then tumbled by 91.83% to $250000.0 in 2023, then soared by 826.4% to $2.3 million in 2024, then tumbled by 38.9% to $1.4 million in 2026.
• The last three Other financing activities figures came in at $1.4 million (Q2 2026), $6.2 million (Q1 2026), and $2.3 million (Q4 2024), per Business Quant data.